RxDoctor Payments Data

Edward Lin, DO

Family Medicine · Milwaukie, ORNPI 1659783546

Payments from drug & device makers

$3,325in general payments, 2019–2025

Across 202 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$652
  • AstraZeneca$398
  • Boehringer Ingelheim$297
  • Biohaven Pharmaceuticals, Inc.$262
  • Lilly USA, LLC$261
  • Kowa Pharmaceuticals America, Inc.$254
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,28899%
  • Education$371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,325 in reported general payments places this provider in the 95th percentile of 1,221 family medicine providers in Oregon.

See all family medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$44,954
Medicare patients
173
Services billed
730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$71,929
TrulicityDulaglutide40$48,058
EliquisApixaban33$37,121
Atorvastatin Calcium381$4,755
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$4,697
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$3,195
Humalog Kwikpen U-100Insulin Lispro13$2,765
Levothyroxine Sodium208$2,579
Albuterol Sulfate HfaAlbuterol Sulfate47$2,057
Losartan Potassium163$1,897
Metformin Hcl ErMetformin Hcl160$1,749
Humulin NInsulin Nph Human Isophane11$1,748
Metoprolol Succinate82$1,335
Simvastatin83$1,235
Potassium Chloride35$1,110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$152$71,92962 claims
Lilly USA, LLCTrulicity, Humulin N$261$49,80651 claims
PfizerEliquis$205$37,12133 claims
AbbVieSynthroid$79$78014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,221 family medicine providers in Oregon.

Other family medicine in Milwaukie

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →